Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
ARPA-H selected five teams for its GIVE research program, with funding of up to $125 million for automated, distributed RNA medicine manufacturing. Selected approaches include RNA synthesis, lipid nanoparticle formulation, fill-finish, and integrated quality control. The agency plans engagement with FDA on regulatory frameworks. These are development objectives for technologies still being built, rather than established distributed GMP production capabilities.
The study develops charge detection mass spectrometry for intact mRNA constructs spanning 997–4,522 nucleotides. Optimized preparation and calibration enabled length determination with 0.5% uncertainty, comparisons of modified nucleotides and poly(A) tails, and analysis after extraction from lipid nanoparticles. The method adds intact-molecule information, while counterion effects and orthogonal identity and impurity measurements remain relevant.
D&D Pharmatech and QIC announced selection for a Korean national R&D program targeting oral α4β7 therapeutics, with a July 2026–June 2028 period and KRW1.358 billion total budget. QIC designs candidates while D&D applies ORALINK and evaluates activity. QIC identifies the program as an oral cyclic peptide in lead optimization, rather than a clinically validated medicine.
CREATE Medicines entered a research collaboration and license agreement with WestGene to combine immune-cell programming and RNA gene-writing technologies with targeted lipid nanoparticles. Initial work spans three in vivo CAR programs involving autoimmune disease, solid tumors, and durable gene expression. The partnership expands delivery access and development options, but the announcement does not demonstrate clinical efficacy of the combined approaches.
BioNTech and Genentech decided to terminate BNT122-01, a Phase 2 trial of autogene cevumeran monotherapy after surgery in ctDNA-positive, high-risk stage II or stage III colorectal cancer. An independent board cited a numerical overall-survival imbalance and the low likelihood that continuing would change the efficacy outcome. No new product safety signals were identified; a pancreatic-cancer combination trial remains unaffected.
Evonik announced a Vancouver expansion for GMP manufacturing of lipid-based drug products, involving more than C$150 million in investment and up to C$68 million in Canadian government support. The project includes production, quality control, and microbiology capabilities. Evonik expects the expansion to more than triple existing capacity; this is planned capacity rather than production already available to customers.
Pfizer and BioNTech announced FDA approval of the 2026–2027 XFG-adapted COMIRNATY formula for adults 65 and older and people ages 5–64 with at least one condition increasing the risk of severe COVID-19. The decision drew on existing clinical, nonclinical, and real-world platform evidence plus formulation-specific quality and nonclinical data. The label does not provide unrestricted use across all age groups.
Quantoom Biosciences and Inside Therapeutics announced a nonexclusive commercial collaboration connecting Ntensify Micro and Mini RNA production with TAMARA lipid nanoparticle formulation. Activities include customer referrals, coordinated marketing, and shared events, while both businesses continue operating and selling independently. The agreement concerns research workflows and commercial coordination, rather than demonstrating a jointly validated, end-to-end GMP manufacturing process.
Electrically neutral self-assembling peptides were developed as mRNA vehicles that form RNA-containing nanotubular assemblies. Experiments examined delivery alongside cytotoxicity and membrane-disruption behavior, reporting favorable readouts in tested systems. This is an alternative peptide carrier rather than an LNP formulation. The peer-reviewed early article supports further development, but its title should not be interpreted as universal or clinical nontoxicity.
Visible-light-driven multicomponent synthesis generated 275 branched amine-containing ionizable lipids from modular building blocks. The platform linked one-pot synthesis with purification-free cell screening and subsequent animal evaluation. A lead lipid improved expression relative to the tested MC3 formulation, and formulation adjustment enabled organ-selective delivery. The work accelerates discovery but does not establish a clinically optimized or validated manufacturing process.
This commentary proposes a lifecycle approach to model-informed decision-making, from discovery and dose selection to regulatory evaluation and reimbursement. It discusses quantitative methods, patient-relevant outcomes, and real-world data, alongside challenges in integration, transparency, and stakeholder acceptance. It is a conceptual roadmap, not a prospective validation of one modeling strategy.
The branched ionizable lipid FL0445 supported delivery of linear mRNA and capped circular RNA through a cholesterol-dependent cellular-entry pathway. In obese mice, GLP-1-encoding capped circular RNA produced sustained expression and improved glucose tolerance relative to tested formulations. Inflammatory transcriptional signals were also assessed. The results provide a preclinical delivery proof of concept, not evidence of clinical metabolic efficacy.
Continue your research
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.
